Search the Newsreel

How Investors May Respond To AbbVie (ABBV) Securing EU Approval For Short-Acting Boey Aesthetic Toxin

In July 2026, Allergan Aesthetics, an AbbVie company, received European Commission approval for Boey (trenibotulinumtoxinE), a rapid-onset, short-duration botulinum neurotoxin serotype E for adults with psychologically impactful moderate to severe glabellar lines, following similar approval in Canada. As the first approved serotype E neurotoxin …

EBIT per share of AbbVie, Inc. – BCS:ABBVCL1

This article provides financial information for AbbVie, Inc. under the ticker ABBVCL1 on the Santiago Stock Exchange, specifically focusing on its EBIT per share. It indicates that the market is currently closed with no trades. The content is primarily a data page from TradingView, …

AbbVie (ABBV) Beats Stock Market Upswing: What Investors Need to Know

AbbVie (ABBV) stock closed up 1.11% in its latest trading session, outperforming the S&P 500 and the Medical sector over the past month. The company is set to release its Q2 earnings on July 31, 2026, with analysts predicting significant growth in EPS and …

Enterprise value of AbbVie, Inc. – BCS:ABBV0

This article from TradingView is a placeholder page for the enterprise value of AbbVie, Inc. (BCS:ABBV0) on the Santiago Stock Exchange. It provides market data, financial links, and community features, but lacks specific valuation data. The page indicates that the market is closed and …

AbbVie Stock Zigs When The Market Zags

AbbVie (ABBV) stock has shown a counter-cyclical pattern, rising even as the broader market declines, with a low correlation to the S&P 500. This is attributed to its strong business fundamentals, including growth in immunology drugs like Skyrizi and Rinvoq, and recent positive Phase …

AbbVie stock advances on a strong 2025 base

AbbVie Inc. stock is supported by its 2025 revenue of $56.33 billion and adjusted diluted EPS of $4.85, along with a quarterly dividend of $1.64 per share. The company's 2024 net revenue of $57.0 billion, a 3.7% increase from 2023, provides a strong comparison …

AbbVie’s Allergan gets European nod for its Botox-lite treatment

AbbVie's Allergan has received European approval for its new "Botox-lite" treatment. This development marks a significant step for Allergan in expanding its cosmetic product offerings within the European market. The article is from Crain's Chicago Business, indicating local relevance for the company's operations.

AbbVie Inc. (ABBV): Investor Outlook Highlights Robust Revenue Growth and Dividend Appeal

AbbVie Inc. (ABBV) continues to attract investor attention with its robust revenue growth of 12.40% and a market capitalization of $449.63 billion. While its dividend yield of 2.72% is appealing, its high payout ratio of 325.98% warrants careful monitoring. Analysts remain largely positive, with …

AbbVie (ABBV) Wins EU Approval For Boey Frown Line Treatment In Europe

AbbVie's Allergan Aesthetics has received European Commission approval for Boey (trenibotulinumtoxinE), a new rapid-onset neurotoxin for treating frown lines. This product aims to expand AbbVie's aesthetics portfolio in Europe by offering patients faster visible effects and more flexible treatment schedules. Investors are encouraged to …

Analysts Are Bullish on Top Healthcare Stocks: Fractyl Health, Inc. (GUTS), AbbVie (ABBV)

Healthcare sector analysts have issued bullish sentiments on Fractyl Health, Inc. (GUTS) and AbbVie (ABBV). H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating for Fractyl Health with an $8.00 price target, while William Blair analyst Matt Phipps maintained a Buy rating for AbbVie. …

AbbVie stock trades steadily as investors weigh Humira erosion and pipeline progress

AbbVie Inc. is navigating a transitional period marked by the decline of its flagship drug Humira due to biosimilar competition, balanced by the growth of its newer immunology and neuroscience treatments. Investors are focusing on the pace at which these new therapies can offset …

Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter?

AbbVie (ABBV) is set to report its second-quarter 2026 results, with investor attention on its neuroscience portfolio following a 26% revenue increase in Q1. The Zacks Consensus Estimate predicts 15% year-over-year growth for neuroscience revenues, driven by drugs like Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, …

Why AbbVie (ABBV) Stock Is Up Today

AbbVie (ABBV) stock rose 3.3% today, driven by positive Wall Street sentiment and anticipation of its second-quarter earnings report. Analyst price target increases and new regulatory submissions for drugs like RINVOQ and SKYRIZI indicate strong pipeline momentum, despite ongoing challenges with Humira. Investors are …

AbbVie Inc Stock (ABBV) Moved Up by 3.32% on Jul 16: What Signal Does It Send?

AbbVie Inc.'s stock (ABBV) rose by 3.32% due to positive clinical trial outcomes for Skyrizi and Rinvoq, reinforcing its post-Humira growth strategy. Institutional investors are favoring healthcare stocks like AbbVie for its dividend profile and resilient cash flow, amidst a broader market shift from …

Is AbbVie (ABBV) Fully Priced Despite Tepkinly Approval And Cash Flow?

AbbVie (ABBV) stock has achieved a 150.7% return over five years, presenting a mixed valuation picture. While a Discounted Cash Flow (DCF) model suggests the stock is undervalued by 46.4% due to strong cash flow and recent Tepkinly approval, market-based multiples, specifically the P/E …

AbbVie’s range-top push rests on June’s 87.5M-share breakout, not fresh July volume

ABBV closed within 0.2% of its 52-week high after a 14.9% four-week run, but the latest advance came on 0.9x volume and leaves valuation distance stretched.

AbbVie Inc (ABBV) director acquisition adds insider angle to a strong tape

The disclosure gives investors a governance marker as the drugmaker trades with heavier turnover and firm relative performance.

AbbVie Inc (ABBV) gets a 17.0% weekly reset on heavy turnover

The healthcare heavyweight’s latest weekly move sharpened a broader four-week advance, though the trend signal has not yet turned active.

AbbVie Stock Leads 3 Cash Flow Picks Trading Below Estimated Value

AbbVie stock slides to lower edge of recent range as buyers show dominance: weekly outlook

ABBVIE ($ABBV) Releases Q1 2026 Earnings

Lobbying Update: $180,000 of ABBVIE INC. lobbying was just disclosed

Lobbying Update: $1,330,000 of ABBVIE INC. lobbying was just disclosed | ABBV Stock News

AbbVie Stock (ABBV) Opinions on Analyst Upgrade and Pipeline Developments